Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice
Takuya Kobayashi, Yoshio Tahara, Mayumi Matsumoto, Masako Iguchi, Hideto Sano, Toshinori Murayama, Hidenori Arai, Hiroji Oida, Takami Yurugi-Kobayashi, Jun K. Yamashita, Hiroyuki Katagiri, Masataka Majima, Masayuki Yokode, Toru Kita, Shuh Narumiya
Takuya Kobayashi, Yoshio Tahara, Mayumi Matsumoto, Masako Iguchi, Hideto Sano, Toshinori Murayama, Hidenori Arai, Hiroji Oida, Takami Yurugi-Kobayashi, Jun K. Yamashita, Hiroyuki Katagiri, Masataka Majima, Masayuki Yokode, Toru Kita, Shuh Narumiya
View: Text | PDF
Article Cardiology

Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice

  • Text
  • PDF
Abstract

Production of thromboxane (TX) A2 and PG I2/prostacyclin (PGI2) is increased in patients with atherosclerosis. However, their roles in atherogenesis have not been critically defined. To examine this issue, we cross-bred atherosclerosis-prone apoE-deficient mice with mice deficient in either the TXA receptor (TP) or the PGI receptor (IP). Although they showed levels of serum cholesterol and triglyceride similar to those of apoE-deficient mice, apoE–/–TP–/– mice exhibited a significant delay in atherogenesis, and apoE–/–IP–/– mice exhibited a significant acceleration in atherogenesis compared with mice deficient in apoE alone. The plaques in apoE–/–IP–/– mice showed partial endothelial disruption and exhibited enhanced expression of ICAM-1 and decreased expression of platelet endothelial cell adhesion molecule 1 (PECAM-1) in the overlying endothelial cells compared with those of apoE–/–TP–/– mice. Platelet activation with thrombin ex vivo revealed higher and lower sensitivity for surface P-selectin expression in platelets of apoE–/–IP–/– and apoE–/–TP–/– mice, respectively, than in those of apoE–/– mice. Intravital microscopy of the common carotid artery revealed a significantly greater number of leukocytes rolling on the vessel walls in apoE–/–IP–/– mice than in either apoE–/–TP–/– or apoE–/– mice. We conclude that TXA2 promotes and PGI2 prevents the initiation and progression of atherogenesis through control of platelet activation and leukocyte-endothelial cell interaction.

Authors

Takuya Kobayashi, Yoshio Tahara, Mayumi Matsumoto, Masako Iguchi, Hideto Sano, Toshinori Murayama, Hidenori Arai, Hiroji Oida, Takami Yurugi-Kobayashi, Jun K. Yamashita, Hiroyuki Katagiri, Masataka Majima, Masayuki Yokode, Toru Kita, Shuh Narumiya

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Generation and atherosclerotic lesions of apoE_/_TP_/_ and apoE_/_IP_/_ ...
Generation and atherosclerotic lesions of apoE_/_TP_/_ and apoE_/_IP_/_ mice. (A) Strategy for PCR analysis of WT and targeted alleles of TP and IP. Primers are shown by arrowheads. Amplified fragments are shown by broken lines. Neo, neomycin-resistance gene. (B) Representative PCR for TP and IP alleles of apoE_/_, apoE_/_TP_/_, and apoE_/_IP_/_ mice. (C) Representative oil red O staining of aortic sinus sections of apoE_/_ (middle), apoE_/_TP_/_ (lower), and apoE_/_IP_/_ (upper) mice. Scale bar: 200 μm. (D) Time course of atherosclerotic lesion development in apoE_/_ (open circles), apoE_/_TP_/_ (filled circles), and apoE_/_IP_/_ (filled squares) mice. Data are means ± SEM (n = 10 for 15-week-old apoE_/_ and apoE_/_IP_/_ and 20-week-old apoE_/_ and apoE_/_TP_/_ male mice; n = 6 for 15-week-old apoE_/_TP_/_, 20-week-old apoE_/_IP_/_, and 30-week-old apoE_/_, apoE_/_TP_/_, and apoE_/_IP_/_ mice). *P < 0.05 and **P < 0.01 versus apoE_/_ mice. (E) Representative Sudan IV staining of en face preparations of aortas from apoE_/_, apoE_/_TP_/_, and apoE_/_IP_/_ mice at 20 weeks of age. Scale bars: 2 mm. (F) Quantification of en face atherosclerotic lesions in apoE_/_, apoE_/_TP_/_ and apoE_/_IP_/_ mice at 20 weeks of age. Data are means ± SEM (n = 5 each). *P < 0.05 and **P < 0.01 for bracketed comparisons. (G) Representative hematoxylin and eosin staining of innominate artery sections of apoE_/_, apoE_/_TP_/_, and apoE_/_IP_/_ mice at 45 weeks of age. Scale bar: 20 μm. (H) Quantitative analysis of innominate atherosclerotic areas in apoE_/_, apoE_/_TP_/_, and apoE_/_IP_/_ mice at 45 weeks of age. Data are means ± SEM (n = 10 each). *P < 0.05 and **P < 0.01 for bracketed comparisons.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts